**Supplementary Table 1.** Results of univariable analysis to predict major adverse cardiovascular events after transcatheter aortic valve implantation using the concentration of indoxyl sulfate and clinical variables

|  |  |  |  |
| --- | --- | --- | --- |
|  | OR | 95% CI | p-value |
|  |  | Lower | Upper |  |
| Indoxyl sulfate, >1650 ng/dL | 8.357 | 2.781 | 25.116 | **< 0.001** |
| TMAO, > 418 ng/dL | 1.016 | 0.736 | 1.403 | **0.921** |
| Age, years  | 1.177 | 1.060 | 1.308 | **0.002** |
| Gender, male | 0.449 | 0.171 | 1.177 | 0.103 |
| BMI, kg/m2  | 0.986 | 0.887 | 1.096 | 0.798 |
| Euroscore II, % | 0.952 | 0.713 | 1.269 | 0.736 |
| Hypertension  | 1.200 | 0.318 | 4.531 | 0.788 |
| Diabetes mellitus  | 0.595 | 0.213 | 1.661 | 0.322 |
| Atral fibrillation  | 1.000 | 0.369 | 2.708 | 1.000 |
| Prior stroke/TIA  | 1.722 | 0.424 | 6.989 | 0.447 |
| Prior myocardial infarction  | 1.169 | 0.411 | 3.329 | 0.770 |
| Prior PCI  | 1.393 | 0.544 | 3.572 | 0.490 |
| Prior CABG  | 0.588 | 0.070 | 4.964 | 0.625 |
| COPD  | 2.165 | 0.608 | 7.706 | 0.233 |
| Heart failure (NYHA ≥ III) | 0.728 | 0.336 | 1.577 | 0.421 |
| CDK > 3a  | 1.867 | 0.637 | 5.469 | 0.255 |
| Haemoglobin, g/dL | 1.191 | 0.949 | 1.493 | 0.131 |
| Creatinine, mg/dL | 0.900 | 0.615 | 1.317 | 0.587 |
| NT-proBNP, pg/mL | 1.000 | 1.000 | 1.000 | 0.849 |
| eGFR, mL/min  | 0.985 | 0.962 | 1.009 | 0.209 |
| Ejection fraction, %  | 1.036 | 0.991 | 1.083 | 0.119 |
| V max, m/s  | 1.256 | 0.523 | 3.019 | 0.610 |
| Gradient max, mmHg | 0.989 | 0.968 | 1.011 | 0.322 |
| Gradient mean, mmHg | 0.969 | 0.935 | 1.004 | **0.081** |
| AVA (VTI) , cm2 | 1.356 | 0.122 | 12.908 | 0.848 |
| AVAi, cm2/m2 | 10.021 | 0.164 | 611.035 | 0.272 |
| Femoral access  | 3.439 | 0.538 | 21.988 | 0.192 |
| Acetylsalicylic acid | 0.511 | 0.183 | 1.423 | 0.199 |
| P2Y12 inhibitor | 0.676 | 0.230 | 1.989 | 0.477 |
| Anticoagulant | 0.998 | 0.704 | 1.414 | 0.990 |
| Beta-blockers | 0.976 | 0.253 | 3.765 | 0.971 |
| RAAS inhibitor | 3.333 | 0.906 | 12.262 | **0.070** |
| MRA | 0.313 | 0.067 | 1.456 | 0.138 |
| Loop diuretics | 3.238 | 0.402 | 26.087 | 0.270 |
| Statins | 1.318 | 0.273 | 6.365 | 0.731 |

AVA — aortic valve area; AVAi — aortic valve area index; BMI — body mass index; CABG — coronary artery bypass graft surgery; CI — confidence interval; COPD — chronic obstructive pulmonary disease; CKD — chronic kidney disease; eGFR — estimated glomerular filtration rate; CRP — C-reactive protein; MACE — major adverse cardiovascular events; MRA — mineralocorticoid receptor antagonists; NT-proBNP — N-terminal pro B natriuretic peptide; NYHA — New York Heart Association; OR — odds ratio; PCI — percutaneous coronary intervention; RAAS — renin-angiotensin-aldosterone system; TAVI — transcatheter aortic valve implantation; TIA — transient ischemic attack

**Supplementary Figure 1.** Receiver operating characteristic curve (ROC) to predict major adverse cardiovascular events after transcatheter aortic valve implantation based on age and baseline plasma level of indoxyl sulfate

